Technical Analysis for PTN - Palatin Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Historical PTN trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Centerline Cross | Bearish | 0.00% | |
Spinning Top | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 50 DMA | Bearish | -4.63% | |
Calm After Storm | Range Contraction | -4.63% | |
Wide Bands | Range Expansion | -4.63% | |
Oversold Stochastic | Weakness | -4.63% | |
Crossed Above 50 DMA | Bullish | -8.31% | |
Calm After Storm | Range Contraction | -8.31% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakdown | 1 day ago | |
Down 5% | 1 day ago | |
Fell Below Previous Day's Low | 1 day ago | |
Down 3% | 1 day ago | |
Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/17/2021
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Diseases Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides C Peptide Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Diseases Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides C Peptide Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.3 |
52 Week Low | 0.35 |
Average Volume | 8,694,365 |
200-Day Moving Average | 0.58 |
50-Day Moving Average | 0.83 |
20-Day Moving Average | 0.97 |
10-Day Moving Average | 0.91 |
Average True Range | 0.11 |
ADX | 28.54 |
+DI | 20.32 |
-DI | 29.19 |
Chandelier Exit (Long, 3 ATRs ) | 0.97 |
Chandelier Exit (Short, 3 ATRs ) | 1.06 |
Upper Bollinger Band | 1.23 |
Lower Bollinger Band | 0.70 |
Percent B (%b) | 0.15 |
BandWidth | 55.04 |
MACD Line | -0.01 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.0429 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.86 | ||||
Resistance 3 (R3) | 0.87 | 0.84 | 0.85 | ||
Resistance 2 (R2) | 0.84 | 0.82 | 0.84 | 0.85 | |
Resistance 1 (R1) | 0.81 | 0.81 | 0.80 | 0.81 | 0.84 |
Pivot Point | 0.79 | 0.79 | 0.78 | 0.79 | 0.79 |
Support 1 (S1) | 0.76 | 0.77 | 0.75 | 0.75 | 0.72 |
Support 2 (S2) | 0.73 | 0.75 | 0.73 | 0.72 | |
Support 3 (S3) | 0.70 | 0.73 | 0.71 | ||
Support 4 (S4) | 0.70 |